AI-generated from publicly available materials.CellCarta and Imagene AI have announced an enhanced collaboration aimed at streamlining the development and deployment of AI-driven biomarker and companion diagnostic programs for biopharma companies.
This partnership focuses on a comprehensive approach that encompasses the entire lifecycle of biomarker programs, from initial strategy and assay development to validation, clinical trials, and regulatory compliance. Currently, they are collaborating on projects with two major pharmaceutical firms, including an AI-enhanced companion diagnostic initiative and a program utilizing Imagene AI’s Lung Prediction Panel for non-small cell lung cancer (NSCLC).
Imagene AI’s capabilities in companion diagnostics leverage quantitative AI pathology to analyze biomarker expression, employing advanced techniques for cell and subcellular analysis, spatial scoring, and patient stratification. Meanwhile, CellCarta supports these efforts by offering a robust infrastructure for clinical trials, validation processes, and regulatory guidance, ensuring that programs can effectively transition from development to market readiness.
This collaboration addresses a critical need in the pharmaceutical sector, as highlighted by industry leaders. The integration of AI in clinical development not only requires sophisticated algorithms but also a solid framework for validation and scalability. By combining their strengths, CellCarta and Imagene AI are poised to significantly enhance the efficiency and effectiveness of biomarker-driven clinical trials, ultimately benefiting patient outcomes in oncology.